肝胆相照论坛

标题: Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral [打印本页]

作者: StephenW 时间: 2012-7-23 02:19 标题: Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral

Hepatology. 2012 Jul 13. doi: 10.1002/hep.25937. [Epub ahead of print]
Prevention of hepatitis B virus-related hepatocellular carcinoma with
antiviral therapy. Lai CL, Yuen MF.

Source
Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Hong Kong; State Key Laboratory for Liver Research, University of Hong
Kong, Queen Mary Hospital, Hong Kong. [email protected].

Abstract
Chronic hepatitis B infection is the major cause of hepatocellular
carcinoma. Primary prevention of hepatitis B infection by vaccination is
effective in reducing the incidence of hepatocellular carcinoma. In persons
with chronic hepatitis B infection, the two accepted treatment modalities
are interferon-alpha given subcutaneously for a limited period and
nucleos(t)ide analogues given orally on a long-term basis. These treatments
are effective in suppressing the viral activity and improving disease
markers in short-term studies. The long-term effect on the development of
liver cancers with these two forms of treatment appears to be different.
However there are no studies directly comparing interferon-alpha and
nucleos(t)ide analogues. Comparisons across studies are inevitably limited
by differences in the baseline characteristics of the study cohorts.
Long-term follow-up studies of interferon-alpha therapy show inconsistent
results. The beneficial effect in reducing the development of liver cancer
is observed mainly in treatment responders who have pre-existing cirrhosis
of the liver. The long-term studies of lamivudine (and adefovir) show a
consistent reduction in the development of liver cancers in patients with,
and without, cirrhosis. This beneficial effect is blunted by the
development of resistance. The effects of the newer nucleos(t)ide
analogues, with higher potency and minimal risk of resistance development,
are as yet unknown. (HEPATOLOGY 2012.). Copyright © 2012 American
Association for the Study of Liver Diseases.

PMID: 22806323 [PubMed - as supplied by publisher]

作者: StephenW 时间: 2012-7-23 02:43

肝病。 2012年七月13日。DOI：10.1002/hep.25937。 [出处提前打印]
预防乙型肝炎病毒有关的肝癌
抗病毒治疗。赖CL元朗中频。

源
医学系，香港大学玛丽医院，
香港，香港大学肝病研究国家重点实验室，
香港玛丽医院，香港。 [email protected]。

抽象
慢性乙型肝炎病毒感染是肝癌的主要病因
癌。通过接种疫苗是预防乙型肝炎病毒感染的主要
有效地降低肝癌的发病率。在人
慢性乙肝病毒感染，接受的治疗方法
α-干扰素皮下注射在有限的时间和
一项长期的基础上给予口服核苷（酸）IDE类似物。这些治疗方法
有效地抑制病毒活性，改善疾病
在短期研究的标志。对发展的长期效应
肝癌治疗这两种形式似乎有所不同。
然而，有没有研究直接比较α-干扰素和
核苷（酸）IDE类似物。整个研究的比较不可避免地有限
研究世代的基线特征差异。
长期跟踪研究α-干扰素治疗表明不一致
结果。在降低肝癌的发展有利的影响
观察主要有预先存在的肝硬化的治疗反应
肝脏。长期研究拉米夫定和阿德福韦显示
一致减少患者在肝癌的发展，
并没有，肝硬化。这种有益的作用正在减弱
发展的阻力。新的核苷（酸）IDE的影响
类似物，具有更高的效力和发展的阻力最小的风险，
是未知数。（2012年肝病。）。版权所有©2012美国
肝病研究协会。

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)